E
EGenesis
A gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues, and cells to address the global organ crisis
About EGenesis
eGenesis is a biotechnology startup that operates in the healthcare sector, specifically in the field of organ transplantation. The company's mission is to address the critical shortage of transplantable organs and cells, a problem that affects over 100,000 people in the U.S. alone. To do this, eGenesis is developing genetically engineered porcine kidneys that are compatible with human bodies, a concept they refer to as Human Compatible (HuCo™) organs and cells.
Read full description
The company's business model revolves around leveraging advanced genetic engineering techniques to create these HuCo™ organs and cells. Once developed, these organs can be transplanted into patients with failing organs, potentially saving their lives and improving their quality of life. The company's primary clients are individuals in need of organ transplants, a demographic that is constantly growing due to the increasing gap between organ demand and supply.
eGenesis generates revenue by selling these genetically engineered organs to healthcare providers who perform the transplants. The company's work is not only potentially life-saving but also financially promising given the high demand for transplantable organs and the limited supply.
In summary, eGenesis is a pioneering biotech startup that is pushing the boundaries of organ transplantation by developing genetically engineered porcine organs that can be transplanted into humans. The company's innovative approach could potentially end the organ shortage crisis and transform the lives of thousands of people waiting for transplants.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Cambridge, United States
- Employees
- 153
- Open positions
- 9
- Dealroom signal
- 86.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Synthetic Biology, Crispr, Spinout, Genome Engineering, Rumoured $1B, Biotech and Pharma, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Sep 2024 | $191M | $764M | Farallon Capital Management · Alta Partners · ARCH Venture Partners · Parkwood | ↗ |
| SERIES COther financing | Mar 2021 | $125M | $500M | Wellington Partners · Farallon Capital Management · Polaris Partners · Khosla Ventures | — |
Growth signals
Latest recorded traffic for EGenesis is 9.4K monthly website visits, up 118.6% over the last three months. EGenesis's team grew 12.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Khosla Ventures
ARCH Venture Partners
Biomatics Capital Partners
Berggruen Holdings
Heritage Provider Network
Alta Partners
Alexandria Venture Investments
Fresenius Medical Care
Wellington Partners
Series B and later18 investors entered at this stage
Farallon Capital Management
Polaris Partners
Osage University Partners- IIIrving Investors
Samsara BioCapital
Monashee Investment Management
Fresenius Medical Care Ventures
Altium Capital
Invus
LifeSci Venture Partners
SymBiosis
Leaps by Bayer
Catalio Capital Management
Lux Capital
Parkwood
DaVita- NPNATCO Pharma
Eisai Innovation
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EGenesis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EGenesis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.